Business
Third quarter 2025 update: IBA is highly confident to meet FY2025 guidance, and strengthens financing structure
Louvain-la-Neuve, Belgium, 20 November 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, shares its business update for the third quarter of 2025. Group Overview Equipment order intake at €195 million as of Q3 2025 (+6% vs. last year) with a strong contribution from IBA Technologies (+22%) driven by RadioPharma Solutions, and four Proteus®ONE solutions sold within IBA Clinical. Equipment and Services backlog stable at €1.3 billion, with sustained backlog
About this update from Ion Beam Applications Sa
[{"type":"image","alt":"IBA SA","displaySize":"","headline":null,"caption":"IBA SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":85,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/ab9cb8d53c1f491c2297f1d9274f5694"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z4qZvB1n65el3DgzVQJgKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTExMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ab9cb8d53c1f491c2297f1d9274f5694","width":85,"height":85}},"lazy":false},{"type":"horizontalRule"},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"Louvain-la-Neuve, Belgium, 20 November 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, shares its business update for the third quarter of 2025.","length":188,"tagName":"p"},{"type":"text","content":"Group Overview","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Equipment order intake at €195 million as of Q3 2025 (+6% vs. last year) with a strong contribution from IBA Technologies (+22%) driven by RadioPharma Solutions, and four Proteus®ONE solutions sold within IBA Clinical. ","length":219,"tagName":"p"}]},{"val":[{"type":"text","content":"Equipment and Services backlog stable at €1.3 billion, with sustained backlog conversion.","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"FY2025 REBIT guidance confirmed: at least €25 million, supported by well under control OpEx and an already positive REBIT contribution from Proton Therapy. At net result level, financials continue to be impacted by foreign exchange fluctuations (primarily USD and CNY).","length":269,"tagName":"p"}]},{"val":[{"type":"text","content":"Net debt position at €60 million1 as of September 30, 2025, with €51 million of revolving credit facilities used. Working capital cycle continues to be driven by the delivery of large proton therapy projects in Spain and China. As a result, net financial position expected to gradually improve as from December 2025.","length":316,"tagName":"p"}]},{"val":[{"type":"text","content":"Closing of a €125 million club deal with leading Belgian and international banks on November 19th, comprising: (i) a €50 million amortizing term loan, (ii) a €15 million amortizing term loan for M&A purposes and (iii) €60 million revolving credit facilities. These partially drawn cred...